Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers led by Mauro Ferrari, Ph.D., develop injectable nanoparticle generator polymeric doxorubicin (iNPG-pDox) to target cancer cells in lungs and liver with limited toxicity. The therapy aims to improve long-term survival and quality of life for triple-negative breast cancer patients.
Researchers have identified a new strategy to target KRAS mutant cancer using a Galectin-3 inhibitor. The study found that binding of the protein to a specific cell surface receptor amplifies the advantages driven by mutant KRAS, creating a unique vulnerability that can be targeted with an existing drug.
A genetic study suggests that existing immunotherapy drugs could help some breast cancer patients with specific genetic changes in their tumors. The research identified a particular group of breast cancer patients who have genetic mutations that occur due to an abnormal DNA repair mechanism.
Researchers identified a potential strategy to improve anti-angiogenesis therapy efficacy by targeting an immunosuppressive pathway in colorectal cancer. Blocking the CXCR4/CXCL12 pathway with an FDA-approved drug, AMD3100, enhanced treatment effects and alleviated immune suppression.
Researchers have developed a novel technique to deliver steroids directly into the cochlea, reducing hearing loss caused by cisplatin treatment in mice by 50%. This breakthrough has potential applications for treating various types of hearing loss and could also be used to deliver other drugs and therapies.
Scientists at UCLA have initiated a phase 1 clinical trial using genetically engineered blood-forming stem cells to produce cancer-fighting white blood cells called T cells. The trial aims to provide both short and long-term immune response to cancer, targeting the NY-ESO-1 tumor marker.
A study by UNC researchers found that the cost of a generic oral chemotherapy treatment was $2,328 last year, which is 36% lower than the projected branded drug price in 2016. However, the savings are modest compared to other generic drugs, and brand-name drug prices have increased over time.
A recent study analyzed U.S. Securities and Exchange Commission filings for 10 companies developing a cancer drug from 2006 through 2015, estimating a median time of 7.3 years to develop the drug and a median cost of $648 million.
A phase III clinical trial found that osimertinib improves progression-free survival and median duration of response by 50-100% compared to standard first line therapy for patients with EGFR mutated non-small-cell lung cancer. The benefit was consistent across all subgroups, including those with and without brain metastases.
The KEYNOTE-059 trial found an overall objective response rate of 12% with pembrolizumab alone in pretreated patients, and more promising activity in patients with newly diagnosed metastatic cancer. The study also showed that patients with PD-L1 expression were more likely to respond to the treatment.
The ARIEL3 trial shows rucaparib maintenance therapy significantly improves progression-free survival in patients with high-grade ovarian cancer and BRCA mutations. The medication also benefits patients with homologous recombination deficient tumors, increasing overall response rates.
A phase 1b clinical trial found that combining pembrolizumab with T-VEC resulted in a 62% overall response rate and a complete response rate of one-third in metastatic melanoma patients. The treatment combination worked by transforming cold tumors into hot ones, allowing pembrolizumab to deliver a beneficial enhancement.
Researchers found that pentoxifylline boosts the effectiveness of immune-checkpoint inhibitors in mice with melanoma, increasing the cure rate to around 40 percent. Disabling regulatory T cells could lead to improved cancer treatment outcomes.
A multi-drug and multi-tumour clinical trial shows that precision oncology using DNA sequencing can identify patient subgroups benefiting from existing drugs. Over 70 patients have started treatment, with a 37% clinical benefit rate observed.
The conference emphasizes that hepatitis C elimination is impossible without prioritizing people who use drugs, as they account for 8% of those living with chronic hepatitis C. New treatments have sparked hope for a world free of the disease, but testing and treatment remain low in many countries.
A new study by Dartmouth researchers has precisely determined the mechanism of cancer drug gemcitabine in human patients, enabling more effective combination therapies and rational clinical trial design. The research bridged the gap between experimental models and human trials, providing valuable insights into the drug's effects on cel...
Patients with hepatocellular carcinoma can start with a lower dose of sorafenib without affecting overall survival, experiencing fewer side effects and lower treatment costs. The reduced dose approach allows patients to ramp up as they show tolerance, while the standard dose may require ramping down due to toxicities.
Early FDG-PET/CT scanning can accurately predict melanoma patients' response to immune checkpoint inhibitor therapy, providing a more effective treatment approach. The study developed criteria with high sensitivity, specificity, and accuracy, identifying a small increase in tumor uptake as an indication of responsiveness.
The ESMO-MCBS version 1.1 is the first major revision, introducing a new scale for single-arm studies in orphan diseases and for diseases with high unmet need. This updated tool will enable users to evaluate single-arm studies, previously only applicable to comparative studies.
Researchers at Cornell University have identified a potential solution to protect premenopausal women from life-altering infertility after cancer treatment. By inhibiting the checkpoint pathway, the study found that oocytes survived radiation and remained fertile, enabling birth of healthy pups.
Research supports e-cigarette use as a smoking cessation aid with consistent daily use increasing the odds of quit success by 10%, but those using e-cigarettes less frequently face lower quit rates.
The FDA has approved Kymriah, a CAR T gene therapy drug, for pediatric and young adult patients with ALL, marking a major milestone in cancer treatment. The therapy showed an exceptional 83 percent success remission rate in clinical trials.
Researchers at UT Health San Antonio have developed a new, first-in-class agent called ERX-11 that blocks the growth of estrogen receptor-positive (ER-positive) breast cancer in its tracks. The new drug has shown promising results in preclinical studies and is expected to begin human trials soon.
Researchers found that Z-endoxifen provided substantial drug exposure, acceptable toxicity, and promising anti-tumor activity in patients with metastatic breast cancer who had progressed on standard anti-estrogen treatments. The treatment resulted in tumor shrinkage, with some cases lasting over two years without disease progression.
Researchers at KAIST have developed a novel method to improve medication treatment for liver cancer, identifying the resistance mechanism of Sorafenib and discovering a new approach to block it. The study suggests the possibility of developing a new method to overcome drug resistance using network analysis.
Researchers analyzed 9,000 proteins in bowel cancer cells to identify networks driving the disease. The study found that proteins can predict drug responses and suggests personalized medicine for patients.
Researchers have discovered a new immunotherapy combination that effectively kills cancer cells, with promising results for treating aggressive breast and rare pediatric muscle cancer. The combination uses existing cancer drugs in a whole new way to stimulate the immune system.
A new microfluidic cell culture device allows researchers to study the development of drug resistance in cancer cells in real-time. The system, developed by Princeton University and Johns Hopkins Medical Institute, provides a tool for preclinical cancer drug development and screening.
Researchers present a comprehensive overview of novel approaches to combating metastatic colorectal cancer, highlighting the potential of immunotherapies and targeted biological agents. The article discusses recent progress and future prospects for these treatments, including combination therapies and overcoming drug resistance.
Researchers found that patients who received canakinumab had a marked reduction in lung cancer incidence and mortality, with death from cancer reduced by half in the highest dosage group. The study suggests that anti-inflammatory therapy may help slow lung cancer progression.
Researchers found that combining CDKs' inhibitors with conventional anti-cancer drugs like cisplatin increases tumor cell death. However, treating cells with 5-FU can lead to decreased death rates and resistance. This study suggests a promising approach for developing new anti-cancer treatments.
Researchers have developed a method that targets cancerous tumors with chemotherapy, delivering the drug directly to cancer cells while protecting healthy cells. The treatment uses nanoparticles and ultrasound to improve delivery, showing promising results in mice experiments.
A team of Cleveland Clinic researchers have discovered a key pathway that leads to recurrence and treatment resistance in endometrial cancer. High levels of CD55 cause cancer stem cells to be more aggressive and resistant to cisplatin than non-stem cell cancer cells.
Researchers at Gladstone Institutes have discovered that a cancer drug called JQ1 can reactivate latent HIV, a critical barrier to a cure. By targeting the BRD4 protein, JQ1 allows the virus to make copies of itself, providing new insights into an 'old' cellular defense mechanism against invading viruses.
Researchers at UC San Diego will study the combination of cirmtuzumab and ibrutinib in a phase Ib/IIa clinical trial to boost remission rates and long-term cancer control for B-cell cancers. The approach targets cancer stem cells, potentially improving complete and lasting remissions.
Researchers have developed a DNA sensor system to measure Topo II enzyme activity, which is crucial for anti-cancer therapy. The system achieved synchronous detection of both Topo II and Topo I in human cell extracts, providing new insights into cancer treatment.
Nutlin-3 targets p53-Mdm2 interaction, enhancing cancer cell growth arrest and apoptosis while producing minimal toxicity. Its potential as an alternative NPC therapy is explored in ongoing clinical trials.
Researchers at The Institute of Cancer Research found a genetic weakness, BTK addiction, that makes oesophageal cancer cells sensitive to ibrutinib. This discovery could lead to a new approach to treatment for oesophageal cancer patients with MYC mutations.
Researchers develop model using zebrafish larvae to predict personalized treatment of cancer, offering faster and safer option than current methods. The study confirms that zebrafish and mice react similarly to treatments, enabling timely answers in under two weeks.
A new study found that annual screening starting at age 40 reduces breast cancer-specific deaths by nearly 40%, compared to 23-31% reductions with other recommendations. The findings suggest that women starting annual mammography at age 40 may benefit from a significant reduction in breast cancer-related deaths.
Researchers at Duke University Medical Center have discovered a molecule, Takinib, that appears to spur cell death in tumors and inflammation. By targeting the TNF-alpha signaling process, Takinib inhibits an enzyme called TAK-1, which controls cell survival.
A study by Queen Mary University of London found that MS drug cladribine improves patients' mobility and self-care, in addition to reducing relapses. The benefits were significant enough for the European Medicines Agency to adopt a positive opinion on licensing the oral preparation.
Researchers discovered that combining a novel drug MI-773 with traditional chemotherapy cisplatin destroyed salivary gland tumor cells and prevented recurrence within 300 days. This combination therapy showed promise in treating adenoid cystic carcinoma, a rare cancer affecting 3,000-4,000 people annually.
Researchers at Dana-Farber Cancer Institute discover that CDK4/6 inhibitors not only halt cancer cell division but also spur the immune system to attack and kill cancer cells. The findings suggest that combining these drugs with immunotherapies may lead to greater anti-cancer effects.
Researchers found that formaldehyde, a toxin, is also used to fuel the one-carbon cycle in cells, producing DNA and amino acids. This discovery could lead to new cancer therapies by targeting this pathway.
A new study by Georgia Institute of Technology researchers has found that a widespread biological concept affecting cancer research could be incorrect up to two-thirds of the time. The study's findings suggest that targeting proteins based on messenger RNA levels may not be optimal, potentially leading to drug targeting errors.
The school has awarded over $3.5 million in grants since its opening in 2014, with the latest grant targeting breast cancer treatment. Dr. Kamaljit Kaur's research aims to develop peptides that target specific receptors on cancer cells, reducing toxic side effects and improving patient survival.
A recent study predicts cancer drug resistance and sensitivity by analyzing genomic alterations and their interactions. Researchers used The Cancer Genome Atlas dataset to create a map of oncogenic dependencies, revealing that certain genetic changes can make tumors resistant to some drugs while making them sensitive to others.
A Yale-led team has identified specific gene combinations that cause deadly brain cancer glioblastoma and found two mutations that make tumors resistant to chemotherapy. The new technology can also pinpoint triggers of other types of cancers.
Researchers found that patients with deeper tumor shrinkage due to targeted treatment had better progression-free survival and overall survival rates. The study suggests that initial response could be an early indicator of a drug's effectiveness, influencing both clinical trials and treatment goals.
Researchers at Mayo Clinic have identified a link between SPOP gene mutations and treatment resistance in prostate cancer. The discovery suggests ways to improve therapy by using these mutations as biomarkers. This breakthrough could lead to more effective treatments for this common and deadly form of cancer.
Researchers from Yale University studied 840 patients with curable cancers and found that those who used only alternative therapy had a higher risk of death. The study suggests that conventional cancer treatment is more effective in improving survival rates.
Researchers at the University of Missouri found that women with increased cadmium levels have a higher risk of endometrial cancer, with rates increasing by 22% in individuals with elevated levels. The study recommends limiting cadmium intake through diet and lifestyle changes to reduce associated cancer risks.
A new hybrid biomaterial delivers a chemotherapeutic agent and RNA interfering technology to silence drug resistance, resulting in substantial decrease in cancer cell viability. The material's ease of modification allows for swapping out components to suit specific cell lines and drugs.
Researchers at the University of Bradford have discovered a new drug candidate, HXR9, that targets HOX genes to prevent cancer cell growth and induce apoptosis. Combining HXR9 with another drug shows enhanced results in reducing cancer growth.
Researchers discovered gold nanoparticles can boost lung cancer treatment effects and reduce side effects by precisely targeting diseased cells. A tiny device containing these particles could potentially be used in humans to activate chemotherapy directly in tumors.
Researchers mapped an acquired mutation altering DNA make-up in 50% of patient tumor samples, identifying a new target for therapy. The discovery highlights the power of mutations to influence epigenetics in cancer cells.
A Tel Aviv University study finds that pre- and post-surgery administration of beta blockers and anti-inflammatory medication significantly reduces metastatic cancer recurrence. The treatment improves long-term survival rates and is safe, inexpensive, and easily administered.
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
Researchers at King Abdullah University of Science & Technology have identified three traditional Saudi plants with potent anticancer substances, including topoisomerase inhibitors. The study suggests these compounds could be used to develop novel cancer treatments, but more research is needed before they can be tested in humans.